1. India Stocks

  2. •

    Healthcare

  3. •

    Medical - Instruments & Supplies
Tarsons Products Limited

Tarsons Products Limited

TARSONS.NS
Tarsons Products LimitedIN flagNational Stock Exchange of India
289.10
INR
+0.40
- -
15.38BMarket Cap
Tarsons Products Limited
TARSONS.NS
(National Stock Exchange of India)

Recent

price

289.10

P/E

ratio

- -

div

yld

- -

ROIC.AI

2019
2020
2021
2022
2023
2024
2025
2026
TTM
FRC
34.88
34.3
44.74
57.83
52.88
55.39
73.82
- -
79.74
Revenue per Share
7.65
7.94
13.52
19.46
15.17
8.01
5.6
- -
2.7
Basic EPS, GAAP
3.42
7.49
0.75
-9.37
-21.49
-15.34
-7.05
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
26.1
33.96
47.51
66.36
79.46
87.45
91.1
- -
2.01
Book Value per Share
26.56
38.72
47.85
94.54
106.9
102.19
106.46
- -
108.49
Tangible Book Value per Share
51
51
51
52
53
53
53
- -
53
Basic Weighted Avg Shares
1,777
1,750
2,279
2,992
2,814
2,947
3,924
4,225
4,225
Sales/Revenue/Turnover
34.62
32.66
40.53
44.84
37.14
21.44
12.29
5.07
5.06
Operating Margin (%)
146
142
137
220
285
404
625
965
965
Depreciation Expense
390
405
689
1,007
807
426
298
143
143
Net Income, GAAP
30.21
23.72
25.49
25.43
25.76
29.83
33.55
34.6
34.6
Effective Tax Rate (%)
21.93
23.16
30.22
33.65
28.69
14.47
7.59
3.39
3.39
Profit Margin (%)
431
794
710
2,096
1,891
221
668
16
16
Working Capital
187
59
33
94
807
1,118
2,123
2,160
2,160
LT Debt
1,353
1,976
2,443
4,898
5,693
6,129
6,302
6,346
6,346
Total Equity
- -
20.13
26.95
25.37
12.98
5.65
3.46
1.4
1.4
Return on Invested Capital (%)
- -
22.1
29.26
32.36
18.69
7.84
5.48
4.74
4.74
Return on Capital (%)
- -
26.48
33.17
34.4
21.07
9.6
6.27
5.79
5.79
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
ST Debt
1,742
- -
1,769
LT Borrowings
2,146
- -
2,095
LT Finance Leases
72
- -
65
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
53
- -
53
Market Capitalization
16,195
12,375
8,821

Working Capital

FRC

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
Total Current Assets
2,541
- -
2,658
Cash, Cash Equivalents & STI
314
- -
254
Accounts Receivable, Net
725
- -
854
Inventories
1,354
- -
1,298
Total Current Liabilities
2,478
- -
2,642
Payables & Accruals
- -
- -
- -
ST Debt
1,742
- -
1,769
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
25.57%
0.69%
Free Cash Flow
- -
-278.67%
-81.04%
Net Income, GAAP
- -
-20.58%
-51.89%
Sales/Revenue/Turnover
- -
14.18%
7.67%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
626
663
618
1,041
2,947
2025
848
992
957
1,127
3,924
2026
914
1,023
1,079
1,209
4,225

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1.8
2.41
1.87
- -
8.01
2025
0.75
1.93
0.99
1.92
5.6
2026
0.34
0.62
0.95
0.79
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
ConvaTec Group Plc (CNVVY)
Safilo Group S.p.A. (SFL.MI)
Lucyd, Inc (LUCY)
Dr. Agarwal's Health Care Limited (AGARWALEYE.NS)
STAAR Surgical Company (STAA)
Straumann Holding AG (STMN.SW)
Business
Tarsons Products Limited is a leading manufacturer and supplier of advanced plastic laboratory products primarily serving the life sciences industry. The company produces a comprehensive range of core products including disposable plastic labware, centrifuge ware, cryo labware, tissue culture ware, liquid handling systems such as pipette tips and microtips, biohazard and safetyware, clinical and microbiology labware, and related laboratory instruments. Tarsons operates a diversified portfolio spanning over 1,700 SKUs across approximately 300 product categories designed for use in molecular biology, cell culture, genomics, proteomics, immunology, and biopharmaceutical research environments. Founded over four decades ago and headquartered in Kolkata, India, Tarsons distributes its products extensively across India and internationally. In a major strategic expansion during the last two years, Tarsons completed the acquisition of the Hamburg-based Nerbe group, including Nerbe R&D GmbH and Nerbe plus GmbH & Co. KG, through its wholly owned subsidiary Tarsons Life Science Pte Ltd, effective January 1, 2024. This acquisition significantly enhances Tarsons’ international market penetration, especially in Europe, and expands its product line to include specialized plastic consumables for life science laboratories. The company is also developing infrastructure by acquiring 6 acres of land at Amta to establish a fulfillment center, radiation facility, and to scale manufacturing capabilities. Tarsons aims to leverage this expanded operational capacity and international footprint to increase exports to approximately 120 countries over the coming decade, underscoring its strategic shift towards global growth. It remains backed by ADV Partners, a global private equity firm. Tarsons Products Limited remains focused on innovation and research and development to customize labware to precise scientific needs, maintaining a strong pan-India distribution network supported by a dedicated sales force. The company continues to emphasize quality, creativity, and service in delivering laboratory solutions geared to improve the accuracy and efficiency of scientific exploration and research. Its broad geographies of operation now include India, Europe, and markets targeted for expansion globally, positioning it as a pivotal supplier within the labware and life sciences consumables segment.